• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $OPT

    Opthea Limited

    Subscribe to $OPT
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: opthea.com

    Peers

    $OPTT

    Recent Analyst Ratings for Opthea Limited

    DatePrice TargetRatingAnalyst
    3/25/2025$2.00Buy → Neutral
    H.C. Wainwright
    3/25/2025$12.00 → $1.00Outperform → Market Perform
    Leerink Partners
    3/25/2025$8.00 → $1.00Buy → Underperform
    Jefferies
    3/24/2025Outperform → Perform
    Oppenheimer
    12/8/2022$14.00Buy
    H.C. Wainwright
    4/26/2022$25.00Outperform
    SVB Leerink
    See more ratings

    Opthea Limited Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Opthea Ltd. downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Opthea Ltd. from Buy to Neutral and set a new price target of $2.00

    3/25/25 8:30:12 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Ltd. downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Opthea Ltd. from Outperform to Market Perform and set a new price target of $1.00 from $12.00 previously

    3/25/25 8:25:42 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Ltd. downgraded by Jefferies with a new price target

    Jefferies downgraded Opthea Ltd. from Buy to Underperform and set a new price target of $1.00 from $8.00 previously

    3/25/25 8:25:11 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Ltd. downgraded by Oppenheimer

    Oppenheimer downgraded Opthea Ltd. from Outperform to Perform

    3/24/25 12:56:47 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Opthea Ltd. with a new price target

    H.C. Wainwright initiated coverage of Opthea Ltd. with a rating of Buy and set a new price target of $14.00

    12/8/22 8:15:53 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVB Leerink initiated coverage on Opthea Ltd. with a new price target

    SVB Leerink initiated coverage of Opthea Ltd. with a rating of Outperform and set a new price target of $25.00

    4/26/22 9:10:17 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Limited SEC Filings

    View All

    SEC Form 6-K filed by Opthea Limited

    6-K - Opthea Ltd (0001815620) (Filer)

    8/19/25 7:32:05 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Opthea Limited

    6-K - Opthea Ltd (0001815620) (Filer)

    8/19/25 6:30:21 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Opthea Limited

    6-K - Opthea Ltd (0001815620) (Filer)

    8/19/25 6:01:56 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Opthea Limited

    6-K - Opthea Ltd (0001815620) (Filer)

    6/2/25 6:05:56 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Opthea Limited

    6-K - Opthea Ltd (0001815620) (Filer)

    4/10/25 6:05:23 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Opthea Limited

    6-K - Opthea Ltd (0001815620) (Filer)

    3/31/25 6:07:14 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Opthea Limited

    6-K - Opthea Ltd (0001815620) (Filer)

    3/24/25 6:06:42 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Opthea Limited

    6-K - Opthea Ltd (0001815620) (Filer)

    3/3/25 6:02:39 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Opthea Limited

    6-K - Opthea Ltd (0001815620) (Filer)

    2/28/25 6:03:58 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Opthea Limited

    6-K - Opthea Ltd (0001815620) (Filer)

    2/26/25 6:01:43 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Limited Press Releases

    Fastest customizable press release news feed in the world

    View All

    Opthea Provides Corporate Update

    Successful DFA settlement reached Company with cash and cash equivalents of approximately USD20M Dr Fred Guerard, CEO, Tom Reilly, CFO, and Sujal Shah, Director, to step down Dr Jeremy Levin to continue as Chairman and to assume additional responsibilities as of September 1st MELBOURNE, Australia and PRINCETON, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), today provided a corporate update following the successful settlement of the Development Funding Agreement ("DFA") with the two investors under the DFA. DFA Settlement In March of 2025, after the primary endpoints were not met in both COAST and ShORe phase 3 clinical trials, Opthea

    8/18/25 7:00:00 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Announces Decision to Discontinue Wet AMD Trials

    ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe trials Opthea continues to consider impact of negative trial results under its Development Funding Agreement (DFA) and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced updates on i

    3/31/25 12:01:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Announces COAST Phase 3 Trial Topline Results

    COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced results from its global Phase 3 clinical trial COAST (Combination OPT-302 with Aflibercept Study) in patients with wet AMD

    3/24/25 12:01:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Announces Phase 2b Wet AMD Publication

    Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina MELBOURNE, Australia and PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the publication of sozinibercept Phase 2b data in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging (OSLI) Retina. The paper entitled "Sozinibercept Combination Therapy for Neovascula

    3/3/25 7:00:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Reports Half Year Results and Business Updates

    Cash and cash equivalents of $131.9M as of December 31, 2024 Cash runway extends through anticipated topline data readouts of COAST (early 2Q CY25) and ShORe (mid-CY25) MELBOURNE, Australia and PRINCETON, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced financial results for the six months ended December 31, 2024, and highlighted recent corporate and clinical updates. "Opthea is making significant progress on its mission to deliver superior

    2/28/25 7:00:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Completes Drug Product PPQ Campaign

    Three consecutive commercial-scale drug product batches successfully produced Supports potential sozinibercept BLA filing in 1H CY2026 MELBOURNE, Australia and PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the completion of its drug product Process Performance Qualification (PPQ) campaign for sozinibercept. The PPQ campaign consisted of the successful production of three consecutive commercial-scale drug product batches requi

    2/26/25 7:00:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Completes COAST Final Week 52 Patient Visit

    COAST Phase 3 trial evaluates superiority and safety of sozinibercept combined with aflibercept in wet AMD Company confirms topline results for COAST anticipated in early 2Q CY25 MELBOURNE, Australia and PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that it has completed the final week 52 patient visit in COAST, the first of two Phase 3 pivotal trials investigating the superiority and safety of sozinibercept in

    2/18/25 7:00:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea to Present at Oppenheimer Healthcare Conference

    MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference and host one-one-one meetings. Details are as follows: Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceDate:February 11-12, 2025Presentation:   Tuesday, February 11, 2025, 10:00 AM ETWebcast Li

    2/7/25 7:00:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Wet AMD Data Featured at Macula Society Meeting

    MELBOURNE, Australia, and PRINCETON, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be highlighted during an oral presentation at the Macula Society 48th Annual Meeting being held   February 12-15, 2025 in Charlotte Harbor, Florida. The Macula Society is a forum for new research in retinal vascular and macular diseases. Details are as follows: Session:Neovascular AMD I: Trials  Timing:Friday, February 14, 2025, 8:0

    2/6/25 7:00:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea to Host Investor Days in New York and Australia

    Updates on commercial insights and readiness plans for sozinibercept in wet AMD Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET In-person events in Sydney on February 3 and Melbourne on February 5 MELBOURNE, Australia and PRINCETON, N.J., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that it will host an Investor Day on Tuesday, January 28, 2025 at 1:30 PM ET in New York City, followed by presentations in Syd

    1/8/25 7:00:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Limited Financials

    Live finance-specific insights

    View All

    Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD

    MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Opthea Limited ((ASX:OPT, NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce that MST Access will host an "Ask the Expert" conference call with Professor Jason S. Slakter, M.D. on Tuesday 13th December 6:30pm – 7:30pm EST USA (Wednesday 14th December 10:30am – 11:30am AEDT). Prof Slakter is a board certified Retinal and Macular Disease Specialist, Clinical Professor of Ophthalmology at New York University School of Medicine, and partner of Vitreous Retina Macula Consultants of New York. Prof Slakter will present an overview of Opthea'

    12/12/22 10:08:46 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Limited Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Opthea Limited

    SC 13G/A - Opthea Ltd (0001815620) (Subject)

    11/14/24 6:00:28 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Opthea Limited

    SC 13G/A - Opthea Ltd (0001815620) (Subject)

    7/3/24 7:15:39 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Opthea Limited (Amendment)

    SC 13G/A - Opthea Ltd (0001815620) (Subject)

    2/14/24 4:21:51 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Opthea Limited (Amendment)

    SC 13G/A - Opthea Ltd (0001815620) (Subject)

    2/14/24 4:17:59 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Opthea Limited (Amendment)

    SC 13G/A - Opthea Ltd (0001815620) (Subject)

    2/15/23 6:01:04 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Opthea Limited (Amendment)

    SC 13G/A - Opthea Ltd (0001815620) (Subject)

    2/14/23 4:00:45 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Opthea Limited (Amendment)

    SC 13G/A - Opthea Ltd (0001815620) (Subject)

    2/14/22 4:21:50 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed

    SC 13G - Opthea Ltd (0001815620) (Subject)

    2/16/21 4:40:06 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Limited Leadership Updates

    Live Leadership Updates

    View All

    Opthea Appoints Kathy Connell to Board of Directors

    Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of Kathy Connell, GAICD, to the Board of Directors (the "Board") as a Non-Executive Director. Ms. Connell's appointment was effective immediately after the Annual General Meeting of the

    11/15/24 7:00:48 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025

    Parisa Zamiri, MD, PhD, and Tom Reilly respectively appointed CMO and CFO Anand Sundaram appointed Vice President Marketing MELBOURNE, Australia and PRINCETON, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced three senior hires as the Company continues to prepare for the sozinibercept Phase 3 topline data readouts of COAST anticipated in early Q2 calendar year 2025 and ShORe in mid calendar year 2025. "Opthea is at an inflection point with

    10/8/24 7:00:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board

    MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announces the formation of its Medical Advisory Board ("MAB") composed of 10 retina thought leaders from countries around the world including the US, Argentina, Australia, China, France, Germany, and Israel. Chaired by Arshad M. Khanani, MD, MA, FASRS, Chief Medical Advisor of Opthea, the MAB's role is to advise the Company on opportunities to address the unmet medical

    7/17/24 7:15:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Appoints John Han, PharmD, as VP Medical Affairs

    MELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of John Han, PharmD, to the role of Vice President, Medical Affairs, effective April 9, 2024. Dr. Han will report to Chief Executive Officer (CEO), Frederic Guerard, PharmD, and will join the Opthea Executive Management Team. Dr. Han brings over 20 years of experience building medical affairs programs and partnering across organizations to lead pre- an

    4/8/24 6:42:02 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Appoints Sujal Shah to the Board of Directors

    MELBOURNE, Australia and PRINCETON, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of Sujal Shah to the Company's Board of Directors (the "Board"), effective April 4, 2024. Concurrent with his appointment as non-Executive Director, Mr. Shah will also become Chairman of the Audit and Risk Committee. In conjunction with Mr. Shah's appointment, the Company also announced that Daniel Spiegelman has resigned from the Board in his role as N

    4/3/24 5:39:25 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor

    MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited ((ASX:OPT, NASDAQ:OPT, "Opthea")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced the appointment of Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor. An internationally recognized retina specialist and clinical scientist, Dr. Khanani is a Managing Partner, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates, and Clinical Associate Professor at the University of Nevada, Reno School of Medicine. "We are delighted to have Dr. Khanani join Opthea as Chief Medical Advisor," said Fred

    2/19/24 6:25:54 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Strengthens Team with Key Clinical and Regulatory Hires

    Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1stExperienced executives bring extensive track record in products for retinal and ophthalmology diseases MELBOURNE, Australia, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited ((ASX:OPT, NASDAQ:OPT, "Opthea")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced the appointment of Julie Clark, MD, MS, as Senior Vice President (SVP), Clinical Development, and Fang Li, Ph.D. RAC, as SVP, Regulatory Affairs, effective February 1, 2024. Dr. Clark and Dr. Li will report to Opthea Chief Executive Officer,

    2/1/24 6:00:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO

    Dr. Megan Baldwin transitions to Founder, Chief Innovation Officer and remains on the Board of Directors Experienced pharmaceutical executives Dr. Frederic Guerard appointed as CEO and Peter Lang appointed as CFO, bringing complementary expertise to lead Opthea's next phase of growth MELBOURNE, Australia, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, ASX:OPT))), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that the company's Chief Executive Officer, Dr. Megan Baldwin, will transition to Founder and Chief Innovation Officer, effective today, reflective of the co

    10/27/23 5:30:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor

    MELBOURNE, Australia, July 10, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, ASX:OPT))), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today  the  resignation of Dr. Joel Naor, Chief Medical Officer (CMO), effective July 15th, 2023.  Dr. Naor is stepping down to pursue new opportunities and will be replaced by Dr. Kenneth Sall, MD who has been appointed as Opthea's Senior Medical Advisor.  Dr. Sall will assume responsibility for safety oversight of the Opthea's Phase 3 clinical trials investigating OPT-302, a novel VEGF-C/D ‘trap' inhibitor, for the treatment of wet age-related macular dege

    7/10/23 6:00:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Opthea Appoints Anshul Thakral as Non-Executive Director of the Board

    MELBOURNE, Australia, June 08, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, ASX:OPT))), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Mr. Anshul Thakral as a Non-Executive Director of the Company's Board of Directors. Concurrently with this appointment, Mr. Michael Sistenich has resigned as a Non-Executive Director, having served for over 7 years on the Board. Opthea's Chairman, Dr. Jeremy Levin, commented "We are immensely grateful to Michael for his contribution to Opthea. Having joined the Board in 2015, Michael has been a valued contributor to Opthea's

    6/8/23 6:00:00 AM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care